

# Hashim Hashim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8362345/publications.pdf>

Version: 2024-02-01

103  
papers

2,738  
citations

257101

24  
h-index

189595

50  
g-index

163  
all docs

163  
docs citations

163  
times ranked

2022  
citing authors

#	ARTICLE	IF	CITATIONS
1	International Continence Society Good Urodynamic Practices and Terms 2016: Urodynamics, uroflowmetry, cystometry, and pressure-flow study. <i>Neurourology and Urodynamics</i> , 2017, 36, 1243-1260.	0.8	373
2	Is the Bladder a Reliable Witness for Predicting Detrusor Overactivity?. <i>Journal of Urology</i> , 2006, 175, 191-194.	0.2	270
3	How should patients with an overactive bladder manipulate their fluid intake?. <i>BJU International</i> , 2008, 102, 62-66.	1.3	200
4	Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. <i>Current Opinion in Urology</i> , 2009, 19, 380-394.	0.9	161
5	International Continence Society (ICS) report on the terminology for nocturia and nocturnal lower urinary tract function. <i>Neurourology and Urodynamics</i> , 2019, 38, 499-508.	0.8	161
6	THE EFFECT OF FLUID INTAKE ON URINARY SYMPTOMS IN WOMEN. <i>Journal of Urology</i> , 2005, 174, 187-189.	0.2	149
7	International Continence Society consensus on the diagnosis and treatment of nocturia. <i>Neurourology and Urodynamics</i> , 2019, 38, 478-498.	0.8	94
8	Fundamentals of urodynamic practice, based on International Continence Society good urodynamic practices recommendations. <i>Neurourology and Urodynamics</i> , 2018, 37, S50-S60.	0.8	84
9	Overactive bladder: an update. <i>Current Opinion in Urology</i> , 2007, 17, 231-236.	0.9	78
10	Drug Treatment of Overactive Bladder. <i>Drugs</i> , 2004, 64, 1643-1656.	4.9	70
11	Ureteropelvic Junction Obstruction. <i>European Urology Supplements</i> , 2012, 11, 25-32.	0.1	69
12	Nocturia: Current Levels of Evidence and Recommendations From the International Consultation on Male Lower Urinary Tract Symptoms. <i>Urology</i> , 2015, 85, 1291-1299.	0.5	56
13	Nocturia think tank: Focus on nocturnal polyuria: ICIERS 2011. <i>Neurourology and Urodynamics</i> , 2012, 31, 330-339.	0.8	55
14	The Arabic ICIQ-UI SF: An alternative language version of the English ICIQ-UI SF. <i>Neurourology and Urodynamics</i> , 2006, 25, 277-282.	0.8	43
15	Nocturia: risk factors and associated comorbidities; findings from the EpiLUTS study. <i>International Journal of Clinical Practice</i> , 2015, 69, 1508-1516.	0.8	43
16	Thinking beyond the bladder: antidiuretic treatment of nocturia. <i>International Journal of Clinical Practice</i> , 2010, 64, 807-816.	0.8	42
17	Antidiuresis therapy: Mechanism of action and clinical implications. <i>Neurourology and Urodynamics</i> , 2007, 26, 1008-1013.	0.8	39
18	Desmopressin, as a co-designer drug, in the treatment of overactive bladder syndrome. <i>Neurourology and Urodynamics</i> , 2009, 28, 40-46.	0.8	38

#	ARTICLE	IF	CITATIONS
19	Nocturia research: Current status and future perspectives. <i>Neurourology and Urodynamics</i> , 2010, 29, 623-628.	0.8	34
20	Would a new definition and classification of nocturia and nocturnal polyuria improve our management of patients? ICI-RS 2014. <i>Neurourology and Urodynamics</i> , 2016, 35, 283-287.	0.8	32
21	Patient preferences for treating refractory overactive bladder in the UK. <i>International Urology and Nephrology</i> , 2015, 47, 1619-1627.	0.6	29
22	Simultaneous in vivo comparison of water-filled and air-filled pressure measurement catheters: Implications for good urodynamic practice. <i>Neurourology and Urodynamics</i> , 2016, 35, 926-933.	0.8	28
23	An Overview of the Diagnosis and Treatment of Erectile Dysfunction. <i>Drugs</i> , 2006, 66, 2339-2355.	4.9	26
24	The use of intravesical gentamicin to treat recurrent urinary tract infections in lower urinary tract dysfunction. <i>Neurourology and Urodynamics</i> , 2017, 36, 2109-2116.	0.8	26
25	The medical management of urinary incontinence. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2010, 152, 4-10.	1.4	25
26	Management of Female and Functional Urology Patients During the COVID Pandemic. <i>European Urology Focus</i> , 2020, 6, 1049-1057.	1.6	25
27	Quality control of uroflowmetry and urodynamic data from two large multicenter studies of male lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2020, 39, 1170-1177.	0.8	25
28	Management of fluid intake in patients with overactive bladder. <i>Current Urology Reports</i> , 2009, 10, 428-433.	1.0	24
29	Pharmacological Management of Women with Mixed Urinary Incontinence. <i>Drugs</i> , 2006, 66, 591-606.	4.9	23
30	Management of recurrent stress urinary incontinence and urinary retention following midurethral sling insertion in women. <i>Annals of the Royal College of Surgeons of England</i> , 2012, 94, 517-522.	0.3	23
31	Thulium laser transurethral vaporesction of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 50-61.	6.3	22
32	Coital Incontinence: What Can We Learn From Urodynamic Assessment?. <i>Urology</i> , 2015, 85, 1034-1038.	0.5	20
33	Constructing trials to show whether urodynamic studies are necessary in lower urinary tract dysfunction. <i>Neurourology and Urodynamics</i> , 2011, 30, 735-740.	0.8	19
34	Risk factors and functional abnormalities associated with adult onset secondary nocturnal enuresis in women. <i>Neurourology and Urodynamics</i> , 2017, 36, 188-191.	0.8	18
35	Transurethral Resection of the Prostate for Benign Prostatic Obstruction: Will It Remain the Gold Standard?. <i>European Urology</i> , 2015, 67, 1097-1098.	0.9	16
36	The Immediate and 6-mo Reproducibility of Pressure-Flow Studies in Men with Benign Prostatic Enlargement. <i>European Urology</i> , 2007, 52, 1186-1194.	0.9	15

#	ARTICLE	IF	CITATIONS
37	Update on the management of overactive bladder. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110390.	0.9	15
38	Bladder wall thickness and urodynamic correlation in children with primary nocturnal enuresis. <i>Journal of Pediatric Urology</i> , 2013, 9, 334-338.	0.6	14
39	A randomised controlled trial to determine the clinical and cost effectiveness of thulium laser transurethral vaporessection of the prostate (ThuVAP) versus transurethral resection of the prostate (TURP) in the National Health Service (NHS) – the UNBLOCS trial: a study protocol for a randomised controlled trial. <i>Trials</i> . 2017. 18. 179.	0.7	13
40	The Future of Urology. <i>European Urology</i> , 2012, 61, 534-540.	0.9	12
41	Basic concepts in nocturia, based on international continence society standards in nocturnal lower urinary tract function. <i>Neurourology and Urodynamics</i> , 2018, 37, S20-S24.	0.8	11
42	New therapies in the treatment of overactive bladder. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 319-337.	1.0	10
43	COVID-19 (SARS-CoV-2) in Non-Airborne body fluids: A systematic review & Meta-analysis. <i>Turkish Journal of Urology</i> , 2021, 47, 87-97.	1.3	10
44	Desmopressin for the treatment of adult nocturia. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 667-683.	0.2	9
45	Emerging drugs for the treatment of benign prostatic obstruction. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 159-174.	1.0	9
46	The association between the ICIQ-LUTS and the ICIQ-bladder diary in assessing LUTS. <i>Neurourology and Urodynamics</i> , 2017, 36, 1601-1606.	0.8	9
47	The role of urodynamics in females with lower urinary tract symptoms. <i>Arab Journal of Urology Arab Association of Urology</i> , 2019, 17, 2-9.	0.7	9
48	Mesh complications: best practice in diagnosis and treatment. <i>Therapeutic Advances in Urology</i> , 2020, 12, 175628722094299.	0.9	9
49	Profile of mirabegron in the treatment of overactive bladder: place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 463-467.	2.0	8
50	Effect of cerebrolysin on bladder function after spinal cord injury in female Wistar rats. <i>International Journal of Urology</i> , 2019, 26, 917-923.	0.5	8
51	Treating Urinary symptoms in Men in Primary Healthcare using non-pharmacological and non-surgical interventions (TRIUMPH) compared with usual care: study protocol for a cluster randomised controlled trial. <i>Trials</i> , 2019, 20, 546.	0.7	8
52	Pathophysiology of urinary incontinence. <i>Surgery</i> , 2017, 35, 287-292.	0.1	7
53	Recent advances in the understanding and management of underactive bladder. <i>F1000Research</i> , 2018, 7, 437.	0.8	7
54	Good urodynamic practice adaptations during the COVID-19 pandemic. <i>Neurourology and Urodynamics</i> , 2020, 39, 1897-1901.	0.8	7

#	ARTICLE	IF	CITATIONS
55	Pathophysiology of urinary incontinence. <i>Surgery</i> , 2020, 38, 185-190.	0.1	7
56	Recent developments in technology for the assessment and management of incontinence. <i>Journal of Medical Engineering and Technology</i> , 2015, 39, 434-440.	0.8	6
57	Ambulatory urodynamics in clinical practice: A single centre experience. <i>Neurourology and Urodynamics</i> , 2019, 38, 2077-2082.	0.8	6
58	The cost-effectiveness of transurethral resection of the prostate vs thulium laser transurethral vaporessection of the prostate in the UNBLOCS randomised controlled trial for benign prostatic obstruction. <i>BJU International</i> , 2020, 126, 595-603.	1.3	6
59	Pharmacological and interventional treatment of benign prostatic obstruction: An evidence-based comparative review. <i>BJUI Compass</i> , 2021, 2, 238-259.	0.7	6
60	Thulium laser transurethral vaporessection versus transurethral resection of the prostate for benign prostatic obstruction: the UNBLOCS RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-96.	1.3	6
61	Vasopressin Receptors in Voiding Dysfunction. <i>Handbook of Experimental Pharmacology</i> , 2011, , 453-483.	0.9	5
62	Clinical application of stem cell therapy in neurogenic bladder: a systematic review and meta-analysis. <i>International Urogynecology Journal</i> , 2021, , 1.	0.7	5
63	Emerging Treatment Options for Benign Prostatic Obstruction. <i>Current Urology Reports</i> , 2011, 12, 247-254.	1.0	4
64	PD24-10 EVALUATION OF THE LEARNING CURVE FOR THULIUM LASER TRANSURETHRAL VAPORESECTION OF THE PROSTATE (THUVARP). <i>Journal of Urology</i> , 2016, 195, .	0.2	4
65	Bladder sensations in women with nocturia due to overactive bladder syndrome. <i>International Urogynecology Journal</i> , 2020, 31, 1041-1048.	0.7	4
66	Current process and outcomes of the surgical management of LUTS due to benign prostatic enlargement: how consistent are we? â€” results from the multi-institutional audit of surgical management of BPE (AuSuM BPE) in the United Kingdom. <i>Scottish Medical Journal</i> , 2021, 66, 58-65.	0.7	4
67	Translation and validation of the Persian ICIQ bladder diary. <i>International Urogynecology Journal</i> , 2021, 32, 3287-3291.	0.7	4
68	Bristol UTrAQ: A proposed system for scoring the technical quality of urodynamic traces. <i>Neurourology and Urodynamics</i> , 2022, 41, 672-678.	0.8	4
69	Treatment of overactive bladder syndrome and detrusor overactivity. <i>Reviews in Gynaecological Practice</i> , 2005, 5, 243-250.	0.1	3
70	Flow meter urine testing: a practical proposition in patients attending for urodynamics?. <i>BJU International</i> , 2006, 97, 1027-1029.	1.3	3
71	The Inflammatory Contracted Bladder. <i>Current Bladder Dysfunction Reports</i> , 2019, 14, 67-74.	0.2	3
72	International Consultation on Incontinence Questionnaireâ€™Satisfaction: psychometric testing of a new patient-reported outcome measure for the evaluation of satisfaction after urological surgery. <i>BJU International</i> , 2020, 126, 286-291.	1.3	3

#	ARTICLE	IF	CITATIONS
73	Trying to predict "dangerous" bladders in children: The area under the curve concept. <i>Journal of Pediatric Urology</i> , 2005, 1, 343-347.	0.6	2
74	Novel uses for antidiuresis. <i>International Journal of Clinical Practice</i> , 2007, 61, 32-36.	0.8	2
75	Modern advancements in minimally invasive surgical treatments for benign prostatic obstruction. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110308.	0.9	2
76	Desmopressin acetate the first sublingual tablet to treat nocturia due to nocturnal polyuria. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 939-954.	1.3	2
77	Efficacy of combination therapy of mid-urethral sling and low-dose AbobotulinumtoxinA injection in mixed urinary incontinence. <i>Neurourology and Urodynamics</i> , 2022, 41, 211-219.	0.8	2
78	Sacral neuromodulation in patients with detrusor underactivity: Is biological sex an indicator?. <i>Neurourology and Urodynamics</i> , 2022, 41, 847-859.	0.8	2
79	Urinoma: A Rare Complication of Abdominal Aortic Aneurysm Surgery. <i>Scientific World Journal</i> , The, 2004, 4, 59-61.	0.8	1
80	Solifenacin in Overactive Bladder. <i>Drugs and Aging</i> , 2005, 22, 1070-1071.	1.3	1
81	Complications of Fungal Cystitis. <i>Current Bladder Dysfunction Reports</i> , 2013, 8, 212-216.	0.2	1
82	Nocturnal polyuria: Literature review of definition, pathophysiology, investigations and treatment. <i>Journal of Clinical Urology</i> , 2019, 12, 60-71.	0.1	1
83	Development of a questionnaire set to evaluate adaptations to COVID era: The ICS TURNOVER project (Transition of fUunctional uRology to New COVID ERa). <i>Neurourology and Urodynamics</i> , 2022, , .	0.8	1
84	The Importance of Terminology for Quantifying Nocturia in Practice. <i>European Urology Focus</i> , 2022, , .	1.6	1
85	Gallstone ileus diagnosed by computed tomography. <i>Medical Journal of Australia</i> , 2003, 179, 305-305.	0.8	0
86	An Unusual Cause of Urinary Retention in the Elderly Patient. <i>Scientific World Journal</i> , The, 2004, 4, 885-886.	0.8	0
87	Re: Stoffel JT, McGuire EJ. 2006. Outcome of urethral closure in patients with neurologic impairment and complete urethral destruction. <i>Neurourol Urodynam</i> 25:19"22. <i>Neurourology and Urodynamics</i> , 2007, 26, 894-894.	0.8	0
88	Oxford Specialist Handbook of Urological Surgery. <i>BJU International</i> , 2009, 104, 1019-1019.	1.3	0
89	Year Book of Urology, 2008. <i>BJU International</i> , 2009, 104, 1793-1793.	1.3	0
90	Overactive Bladder Syndrome. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2010, 16, 311-312.	0.6	0

#	ARTICLE	IF	CITATIONS
91	New developments in the diagnosis and management of overactive bladder. Clinical Practice (London,) Tj ETQq1 1 0.784314 0.1 0	0.1	0
92	Robotic ileocystoplasty and bladder neck artificial urinary sphincter insertion: Video demonstration of technique. Urology Video Journal, 2019, 3, 100009.	0.1	0
93	Treatment options for the overactive bladder syndrome. Therapy: Open Access in Clinical Medicine, 2005, 2, 921-936.	0.2	0
94	Treatment options for the overactive bladder syndrome. Therapy: Open Access in Clinical Medicine, 2005, 2, 921-936.	0.2	0
95	Nocturia. Bjuj, 2011, , .	0.0	0
96	Chapter 5 Treatment of overactive bladder syndrome and stress urinary incontinence. , 2011, , .		0
97	Appendix International Consultation and National Institute for Health and Clinical Excellence (NICE) guidelines. , 2011, , .		0
98	Chapter 1 Definition of overactive bladder syndrome and stress urinary incontinence. , 2011, , .		0
99	Chapter 2 Epidemiology of overactive bladder syndrome and urinary incontinence. , 2011, , .		0
100	Dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic enlargement. Drugs of Today, 2012, 48, 17.	0.7	0
101	Postoperative Emergencies After Urological Surgery. , 2013, , 205-222.		0
102	Other Infective Urological Emergencies. , 2013, , 59-70.		0
103	Treatment of Storage LUTS. , 2020, , 169-216.		0